For: | Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553 [PMID: 30386104 DOI: 10.3748/wjg.v24.i40.4548] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v24/i40/4548.htm |
Number | Citing Articles |
1 |
Amy B. Howell, Li-Shu Wang. Potential of cranberry for suppressing Helicobacter pylori, a risk factor for gastric cancer. Journal of Berry Research 2020; 10(1): 11 doi: 10.3233/JBR-180375
|
2 |
Youn I Choi, Sung Min Lee, Jun-Won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Jung Ho Kim, Sun Mi Lee, Jin-Yong Jeong, Dong Kyun Park. Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Helicobacter Eradication in Korea: An In Vitro Culture-Based Study. Antibiotics 2021; 10(10): 1242 doi: 10.3390/antibiotics10101242
|
3 |
Najmeh Salehi, Bahareh Attaran, Negin Eskini, Maryam Esmaeili, Atefeh Sharifirad, Mehdi Sadeghi, Marjan Mohammadi. New insights into resistance of Helicobacter pylori against third‐ and fourth‐generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations. Helicobacter 2019; 24(5) doi: 10.1111/hel.12628
|
4 |
Mohammad Hossein Peypar, Amin Vesal Yeganeh, Ali Ramazani, Arman Alizadeh, Mahdi Abdorrashidi, Amirmohammad Tohidinia, Mohammad Mahdi Shamlou, Mohammad Heiat. Oral immunotherapy for Helicobacter pylori: Can it be trusted? A systematic review. Helicobacter 2024; 29(2) doi: 10.1111/hel.13067
|
5 |
Natsuda Aumpan, Varocha Mahachai, Ratha‐korn Vilaichone. Management of Helicobacter pylori infection. JGH Open 2023; 7(1): 3 doi: 10.1002/jgh3.12843
|
6 |
Najmeh Salehi, Bahareh Attaran, Fatemeh Zare‐Mirakabad, Bahareh Ghadiri, Maryam Esmaeili, Mohadeseh Shakaram, Mohammad Tashakoripour, Mahmoud Eshagh Hosseini, Marjan Mohammadi. The outward shift of clarithromycin binding to the ribosome in mutantHelicobacter pyloristrains. Helicobacter 2020; 25(6) doi: 10.1111/hel.12731
|
7 |
Yiying Pei, Daphne Ang, Andrew Boon Eu Kwek, Tiing Leong Ang. Changing profile of Helicobacter pylori primary antibiotic resistance in Singapore over two decades. Journal of Digestive Diseases 2022; 23(5-6): 295 doi: 10.1111/1751-2980.13115
|
8 |
Sha Cheng, Huan Li, Ju Luo, Jingshu Chi, Wenfang Zhao, Jiahui Lin, Canxia Xu. Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: a single-center, randomized, controlled study. Frontiers in Microbiology 2023; 14 doi: 10.3389/fmicb.2023.1150129
|
9 |
Anastasia Dmitrieva, Oksana Kozlova, Victor Atuchin, Irina Milentieva, Anna Vesnina, Svetlana Ivanova, Lyudmila Asyakina, Alexander Prosekov. Study of the Effect of Baicalin from Scutellaria baicalensis on the Gastrointestinal Tract Normoflora and Helicobacter pylori. International Journal of Molecular Sciences 2023; 24(15): 11906 doi: 10.3390/ijms241511906
|
10 |
Irena Mladenova. Clinical Relevance of Helicobacter pylori Infection. Journal of Clinical Medicine 2021; 10(16): 3473 doi: 10.3390/jcm10163473
|
11 |
Asghar Ali, Khalid I. AlHussaini. Helicobacter pylori: A Contemporary Perspective on Pathogenesis, Diagnosis and Treatment Strategies. Microorganisms 2024; 12(1): 222 doi: 10.3390/microorganisms12010222
|
12 |
Paula Roszczenko-Jasińska, Marta Ilona Wojtyś, Elżbieta K. Jagusztyn-Krynicka. Helicobacter pylori treatment in the post-antibiotics era—searching for new drug targets. Applied Microbiology and Biotechnology 2020; 104(23): 9891 doi: 10.1007/s00253-020-10945-w
|
13 |
Xiao-Jian He, Xiang-Peng Zeng, Chuan-Shen Jiang, Gang Liu, Da-Zhou Li, Wen Wang. Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China. Digestive Diseases and Sciences 2022; 67(1): 208 doi: 10.1007/s10620-021-06856-z
|
14 |
Wen Gao, Guigen Teng, Chi Wang, Ying Xu, Yixuan Li, Hong Cheng. Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China. Helicobacter 2022; 27(5) doi: 10.1111/hel.12918
|
15 |
Chao Ran Ji, Jing Liu, Yue Yue Li, Chen Qiao, Jun Yan Qu, Jun Nan Hu, Min Juan Lin, Rui Ji, Li Xiang Li, Xiu Li Zuo, Yan Qing Li. Susceptibility‐guided quadruple therapy is not superior to medication history‐guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. Journal of Digestive Diseases 2020; 21(10): 549 doi: 10.1111/1751-2980.12934
|
16 |
Sho Suzuki, Mitsuru Esaki, Chika Kusano, Hisatomo Ikehara, Takuji Gotoda. Development of <i>Helicobacter pylori</i> treatment: How do we manage antimicrobial resistance?. World Journal of Gastroenterology 2019; 25(16): 1907-1912 doi: 10.3748/wjg.v25.i16.1907
|
17 |
Tony A. Shindano, Manix I. Masimango, Antoine S. Kishabongo. Efficacy and tolerability of Helicobacter pylori eradication regimes in South Kivu, Eastern of the Democratic Republic of Congo: A single center observational study. Health Science Reports 2024; 7(3) doi: 10.1002/hsr2.1960
|
18 |
Ji Yong Hwang, Changho Kim, Yong Hwan Kwon, Ji Eun Lee, Seong Woo Jeon, Su Youn Nam, An Na Seo, Man-Hoon Han, Ji Hye Park. Dual Clarithromycin and Metronidazole Resistance Is the Main Cause of Failure in Ultimate <b><i>Helicobacter pylori</i></b> Eradication. Digestive Diseases 2021; 39(5): 451 doi: 10.1159/000514278
|
19 |
Snehal Sambhaji Misal, Vedant Balasaheb Bhor, Ramaa Subramanian Chelakara. Structural Insights into Potent Anti-ulcer Agents for the Eradication of Helicobacter pylori. Anti-Infective Agents 2024; 22(5) doi: 10.2174/0122113525296549240402074618
|
20 |
Thaís da Silva Moraes, Lucas Kozoski de Lima, Rodrigo Cássio Sola Veneziani, Sérgio Ricardo Ambrósio, Raquel Alves dos Santos, Jonas Joaquim Mangabeira da Silva, Gustavo Lima Ribeiro, Jairo Kenupp Bastos, Carlos Henrique Gomes Martins. In vitro Antibacterial Potential of the Oleoresin, Leaf Crude Hydroalcoholic Extracts and Isolated Compounds of the Copaifera spp. Against Helicobacter pylori. Journal of Biologically Active Products from Nature 2021; 11(2): 183 doi: 10.1080/22311866.2021.1914730
|
21 |
D. Mark Pritchard, Jan Bornschein, Ian Beales, Ariel Beresniak, Hocine Salhi, Peter Malfertheiner. Cost-effectiveness modelling of use of urea breath test for the management ofHelicobacter pylori-related dyspepsia and peptic ulcer in the UK. BMJ Open Gastroenterology 2021; 8(1): e000685 doi: 10.1136/bmjgast-2021-000685
|
22 |
Dina A. Gawad, Mai M. Elnaggar, Tarek S. Belal. Multi-analyte HPLC–DAD Method for Concurrent Analysis of Six Antimicrobials and Three Proton Pump Inhibitors Frequently used in Management of Helicobacter pylori Infection: Application to Simulated Intestinal Fluid Samples. Chromatographia 2022; 85(7): 617 doi: 10.1007/s10337-022-04168-6
|
23 |
Youn I Choi, Jun Won Chung, Dong Kyun Park, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Ja Young Seo. Tailored eradication <i>vs</i> empirical bismuth-containing quadruple therapy for first-line <i>Helicobacter pylori</i> eradication: A comparative, open trial. World Journal of Gastroenterology 2019; 25(46): 6743-6751 doi: 10.3748/wjg.v25.i46.6743
|
24 |
Javier David Lara Icaza, Rosalina Lara Tapia, Cástula Tania Castro Triana, Laura Catalina Romero Ramírez. Refractoriness to anti‐Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil‐Ecuador. Helicobacter 2024; 29(2) doi: 10.1111/hel.13060
|
25 |
Ying-Chao Sun, Meng-Jia Zhu, Xue-Qin Chen, Lei Yue, Yi-Ru Zhao, Xin-Jie Wang, John J Kim, Qin Du, Wei-Ling Hu. Efficacy and safety of modified tetracycline dosing in a quadruple therapy for <i>Helicobacter pylori</i>: A retrospective single center study. World Journal of Gastroenterology 2023; 29(22): 3508-3518 doi: 10.3748/wjg.v29.i22.3508
|
26 |
Ping‐I Hsu, Feng‐Woei Tsay, John Y. Kao, Nan‐Jing Peng, Yan‐Hua Chen, Sheng‐Yeh Tang, Chao‐Hung Kuo, Sung‐Shuo Kao, Huay‐Min Wang, I‐Ting Wu, Chang‐Bih Shie, Seng‐Kee Chuah, Deng‐Chyang Wu. Tetracycline‐levofloxacin versus amoxicillin‐levofloxacin quadruple therapies in the second‐line treatment of Helicobacter pylori infection. Helicobacter 2021; 26(5) doi: 10.1111/hel.12840
|
27 |
Omnia Momtaz Al-Fakhrany, Engy Elekhnawy. Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents. Archives of Microbiology 2023; 205(9) doi: 10.1007/s00203-023-03639-0
|
28 |
Stella I. Smith, Abraham Ajayi, Tolulope F. Jolaiya, Utibeima Essiet. Prevalence, diagnosis and treatment of Helicobacter pylori infection in Nigeria. Nigerian Journal of Gastroenterology and Hepatology 2022; 14(1): 2 doi: 10.4103/njgh.njgh_10_22
|
29 |
Fan Zhang, Cong Chen, Jike Hu, Ruiliang Su, Junqiang Zhang, Zhijian Han, Hao Chen, Yumin Li. Molecular mechanism of Helicobacter�pylori‑induced autophagy in gastric cancer (Review). Oncology Letters 2019; doi: 10.3892/ol.2019.10976
|
30 |
Giuseppe Losurdo, Fulvio Salvatore D’Abramo, Mariapaola Piazzolla, Raffaella Rima, Antonio Continisio, Maria Pricci, Enzo Ierardi, Alfredo Di Leo. Second-line Therapy for Helicobacter Pylori Eradication: State of the Art. Mini-Reviews in Medicinal Chemistry 2022; 22(19): 2430 doi: 10.2174/1389557522666220325153832
|